Head and neck tumor cells treated with hypofractionated irradiation die via apoptosis and are better taken up by M1-like macrophages.
Head and neck cancer
Human papilloma virus
Macrophage polarization
Phagocytosis
Radiotherapy
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
21
06
2021
accepted:
15
09
2021
pubmed:
20
10
2021
medline:
31
3
2022
entrez:
19
10
2021
Statut:
ppublish
Résumé
The incidence of head and neck squamous cell carcinomas (HNSCC) is increasing worldwide, especially when triggered by the human papilloma virus (HPV). Radiotherapy has immune-modulatory properties, but the role of macrophages present in HNSCC and having contact with irradiated tumor cells remains unclear. The influence of irradiated (2 × 5Gy) HNSCC cells on the (re-)polarization and phagocytosis of human macrophages, either non-polarized or with a more M1 or M2 phenotype, was therefore investigated. Human monocytes were differentiated with the hematopoietic growth factors M‑CSF (m) or GM-CSF (g) and additionally pre-polarized with either interleukin (IL)-4 and IL-10 or interferon (IFN)-γ and lipopolysaccharides (LPS), respectively. Subsequently, they were added to previously irradiated (2 × 5Gy) and mock-treated HPV-positive (UD-SCC-2) and HPV-negative (Cal33) HNSCC cells including their supernatants. The HNSCC cells treated with hypofractionated irradiation died via apoptosis and were strongly phagocytosed by M0m and M2 macrophages. M0g and M1 macrophages phagocytosed the tumor cells to a lesser extent. Irradiated HNSCC cells were better phagocytosed by M1 macrophages compared to mock-treated controls. The polarization status of the macrophages was not significantly changed, except for the expression of CD206 on M2 macrophages, which was reduced after phagocytosis of irradiated HPV-negative cells. Further, a significant increase in the uptake of irradiated HPV-positive cells by M0g macrophages when compared to HPV-negative cells was observed. HNSCC cells treated with hypofractionated irradiation foster phagocytosis by anti-tumorigenic M1 macrophages. The data provide the first evidence on the impact of the HPV status of HNSCC cells on the modulation of the macrophage response to irradiated tumor cells.
Identifiants
pubmed: 34665291
doi: 10.1007/s00066-021-01856-4
pii: 10.1007/s00066-021-01856-4
pmc: PMC8789708
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-182Informations de copyright
© 2021. The Author(s).
Références
Cell Death Differ. 2001 Apr;8(4):327-34
pubmed: 11550084
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32217759
Front Oncol. 2012 Aug 06;2:89
pubmed: 22888475
Trends Immunol. 2012 Mar;33(3):119-26
pubmed: 22277903
Head Neck Oncol. 2013 Feb 27;5(3):24
pubmed: 24723971
Eur J Immunol. 2007 Jan;37(1):14-6
pubmed: 17183610
Nat Cell Biol. 2005 Dec;7(12):1161-3
pubmed: 16319968
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Jun;162(2):79-82
pubmed: 29765169
Cancer Immunol Immunother. 2016 Jul;65(7):779-86
pubmed: 26590829
J Immunother Cancer. 2019 Jan 15;7(1):10
pubmed: 30646957
Immunity. 2016 Mar 15;44(3):463-475
pubmed: 26982354
Lancet Oncol. 2009 Jul;10(7):718-26
pubmed: 19573801
Technol Cancer Res Treat. 2013 Jun;12(3):259-67
pubmed: 23289476
Pathol Int. 2011 Sep;61(9):528-35
pubmed: 21884302
Cancer Treat Rev. 2015 Dec;41(10):844-52
pubmed: 26476574
Eur J Cancer. 2006 Apr;42(6):717-27
pubmed: 16520032
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Pathol Int. 2009 May;59(5):300-5
pubmed: 19432671
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Cell. 2010 Mar 19;140(6):798-804
pubmed: 20303871
J Pathol. 2013 Jan;229(2):176-85
pubmed: 23096265
Scand J Immunol. 2014 May;79(5):305-14
pubmed: 24521472
Med Hypotheses. 2016 Sep;94:118-22
pubmed: 27515216
Int J Cancer. 2009 Jul 15;125(2):367-73
pubmed: 19378341
PLoS One. 2013 Oct 21;8(10):e78045
pubmed: 24205083
J Exp Med. 1994 Aug 1;180(2):705-9
pubmed: 8046345
Immunotherapy. 2014;6(5):597-610
pubmed: 24896628
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Curr Opin Immunol. 2012 Apr;24(2):225-32
pubmed: 22310103
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Nat Rev Cancer. 2019 Oct;19(10):568-586
pubmed: 31462760
Oral Oncol. 2016 Jan;52:75-84
pubmed: 26728105
J Am Coll Cardiol. 2011 Jul 12;58(3):248-55
pubmed: 21737014
J Exp Med. 1992 Jul 1;176(1):287-92
pubmed: 1613462
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Front Immunol. 2016 Jul 19;7:275
pubmed: 27486460
Sci Immunol. 2016 Sep;1(3):
pubmed: 28018989
Cancer Cell. 2013 Mar 18;23(3):277-86
pubmed: 23518347
Cell Mol Immunol. 2011 Jan;8(1):59-66
pubmed: 21200385
Radiother Oncol. 2012 Apr;103(1):49-56
pubmed: 22410204
Methods Enzymol. 2020;632:133-154
pubmed: 32000893
Radiother Oncol. 2013 May;107(2):242-6
pubmed: 23602369
Hum Immunol. 2009 May;70(5):325-30
pubmed: 19236898
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
Cancer Biol Ther. 2014 Jan;15(1):99-107
pubmed: 24100343
J Pathol. 2002 Mar;196(3):254-65
pubmed: 11857487
J Exp Med. 2004 Nov 1;200(9):1157-65
pubmed: 15504819
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
J Immunol. 2006 Nov 15;177(10):7303-11
pubmed: 17082649
J Surg Res. 2011 May 15;167(2):e211-9
pubmed: 19765725
Radiother Oncol. 2019 Jan;130:89-96
pubmed: 30172455
Sci Rep. 2016 Jun 08;6:27548
pubmed: 27271009
Cancer Immunol Immunother. 2021 Apr;70(4):1015-1029
pubmed: 33104837
Cancer Res. 2006 Jan 15;66(2):605-12
pubmed: 16423985
J Cell Physiol. 2018 Sep;233(9):6425-6440
pubmed: 29319160
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Clin Dev Immunol. 2012;2012:948098
pubmed: 22778768
Br J Cancer. 2002 Nov 18;87(11):1227-9
pubmed: 12439710
Stem Cell Rev Rep. 2013 Oct;9(5):620-41
pubmed: 23812784
J Craniomaxillofac Surg. 2014 Oct;42(7):1087-94
pubmed: 24556525
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 May;109(5):744-52
pubmed: 20303300
Cancer Cell Int. 2018 Aug 28;18:120
pubmed: 30181713
Trends Immunol. 2009 Nov;30(11):531-7
pubmed: 19699678
PLoS One. 2017 Jul 21;12(7):e0181108
pubmed: 28732044
Oral Oncol. 2009 Apr-May;45(4-5):454-60
pubmed: 18804412
Clin Oncol (R Coll Radiol). 2016 Jul;28(7):467-74
pubmed: 27052795
Cytokine. 2018 May;105:63-72
pubmed: 29459345
Ann Oncol. 2017 Oct 1;28(10):2386-2398
pubmed: 28633362
Br J Cancer. 2013 Mar 5;108(4):914-23
pubmed: 23385730
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
J Oral Pathol Med. 2012 Jul;41(6):444-51
pubmed: 22296275
J Leukoc Biol. 2011 Apr;89(4):557-63
pubmed: 21248152
J Immunol Methods. 2012 Jan 31;375(1-2):196-206
pubmed: 22075274
J Immunother Cancer. 2020 Dec;8(2):
pubmed: 33335026
Sci Transl Med. 2010 Dec 22;2(63):63ra94
pubmed: 21178137
Nat Med. 2015 Feb;21(2):117-9
pubmed: 25654601
Biochim Biophys Acta. 2010 Jan;1805(1):53-71
pubmed: 19720113
Immunity. 2011 Oct 28;35(4):445-55
pubmed: 22035837
PLoS One. 2013 Nov 15;8(11):e80908
pubmed: 24260507
Diagn Pathol. 2017 Apr 5;12(1):32
pubmed: 28381274
Oral Oncol. 2016 Mar;54:15-27
pubmed: 26794879
Am J Clin Pathol. 2004 Nov;122(5):794-801
pubmed: 15491976
Cancer Res. 2013 Aug 1;73(15):4791-800
pubmed: 23749640
Clin Cancer Res. 2019 Jul 15;25(14):4211-4223
pubmed: 30814108
J Am Soc Nephrol. 2011 Feb;22(2):317-26
pubmed: 21289217
Front Oncol. 2019 Mar 06;9:122
pubmed: 30895168
J Leukoc Biol. 2004 Sep;76(3):509-13
pubmed: 15218057
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):126-137
pubmed: 30605716
Cureus. 2020 Oct 15;12(10):e10964
pubmed: 33209523
J Thorac Dis. 2014 Apr;6(4):287-302
pubmed: 24688774
Front Immunol. 2014 Oct 17;5:514
pubmed: 25368618
Front Immunol. 2019 Dec 03;10:2831
pubmed: 31849993
Int J Cancer. 2002 Mar 20;98(3):440-5
pubmed: 11920597
Eur J Immunol. 1993 Sep;23(9):2320-5
pubmed: 8370408
Clin Exp Immunol. 2005 Dec;142(3):481-9
pubmed: 16297160
J Exp Med. 2008 Jun 9;205(6):1261-8
pubmed: 18490490
Strahlenther Onkol. 2020 Oct;196(10):913-921
pubmed: 32025804
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
Oncotarget. 2014 Jan 30;5(2):403-16
pubmed: 24480782
Nat Rev Immunol. 2012 Mar 22;12(4):253-68
pubmed: 22437938